TruScreen Group Limited Stock

Truscreen Group Limited is a New Zealand-based medical device company. The Company is engaged in the development of an artificial intelligence (AI)-enabled device that can detect precancerous and cancerous cervical changes in real-time via optical and electrical measurements of cervical tissue. The Company’s cervical screening technology resolves ongoing issues with cytology, including failed samples, poor patient follow-up, patient discomfort, and the need for supporting laboratory infrastructure. The TruScreen device uses opto-electrical technology to evaluate the tissue of the cervix. The TruScreen device consists of a disposable Single Use Sensor (SUS), a Handheld Device (HHD), and an Intelligent Cradle (IC) which works together to detect and identify cancerous and precancerous changes to the cervix. It also resolves the problems associated with human papillomavirus (HPV) testing, which tests for the much more prevalent HPV virus.